ICICI Securities Ltd | Retail Equity Research Revenues increased 7% YoY to | 1492 crore (I-direct estimate: | 1534 crore). Pharmaceutical segment grew 15% YoY to | 829 crore (I-direct estimate: | 873 crore) while life science ingredients (LSI) declined 3% YoY to | 663 crore (I-direct estimate: | 640 crore) EBITDA margins increased 40 bps YoY to 22.2%. However, margins were below I-direct estimate of 25.5%, mainly due to lower-thanexpected EBITDA margins in the LSI segment. EBITDA increased 8% YoY to | 332 crore (I-direct estimates: | 390 crore)...